Every cancer has its own molecular blueprint. When standard immunotherapy fails, doctors can sequence thousands of biomarkers across DNA, RNA, and immune cells to design a custom treatment for that specific tumor.
Each cancer is unique. It has a different blueprint. It's heterogeneous. When you test thousands of markers, they are different. Two colon cancers, pancreatic, endometrial, gastric, breast, all the cancers have unique markers. But with deep N-of-1 precision targeting, multiomics, next-generation sequencing DNA, hundreds of markers, RNA transcriptomics, now we're getting into 1,000+ markers, spatial biology and immunity. Now we can build custom immunotherapies and change the tumor's information.
